Oncology

Increased Competition Is Lowering Trastuzumab Prices

June 14th 2023

By Skylar Jeremias

Article

After 8 years of trastuzumab biosimilar competition and slow uptake, a new report shows that trastuzumab biosimilar discounts from the reference product (Herceptin) doubled between 2019 and 2022.

Biosimilars Business News Recap: A New Partnership; Celltrion Wins Tenders

May 17th 2023

By Skylar Jeremias

Article

As Sandoz and Just-Evotec Biologics announce a new partnership, Celltrion secures tender wins in Italy and Belgium, and Alvotech begins testing its golimumab biosimilar in patients with rheumatoid arthritis.

Fylnetra Launches in the United States

May 16th 2023

By Skylar Jeremias

Article

Amneal Pharmaceuticals has announced the launch of its pegfilgrastim biosimilar, Fylnetra (pegfilgrastim-pbbk), for the treatment and prevention of febrile neutropenia, making it the sixth biosimilar referencing Neulasta to enter the US market.

Samsung Bioepis Report Correlates Biosimilar Pricing Changes With Market Adoption

May 10th 2023

By Skylar Jeremias

Article

In the first edition of Samsung Bioepis’ Biosimilar Market Report, the company outlined the current state of the US biosimilars market and how increasing adoption has had an impact on pricing changes for biosimilars and their reference products.

Dr Andre Harvin Answers How Oncologists Can Work to Expand Access to Biosimilars

May 7th 2023

By Skylar Jeremias

Video

Andre Harvin, PharmD, executive director of pharmacy and oncology services at Cone Health, explains how oncologists can work with other stakeholders to expand access to biosimilars and how patients can work with providers and biosimilar manufacturers to address financial challenges.

Long-term Phase 3 Results Show Similar Efficacy, Cardiac Safety of SB3 vs Herceptin

May 6th 2023

By Deana Ferreri, PhD

Article

The authors of what they say is the largest and longest follow-up study comparing the trastuzumab biosimilar SB3 to the reference product (Herceptin) in HER2-positive breast cancer found “no clinically meaningful difference” between the biosimilar and the reference product.

Despite Concerns Over Extrapolation, Bevacizumab Biosimilars Are Widely Used in mCRC

May 3rd 2023

By Deana Ferreri, PhD

Article

A review article investigating the use of bevacizumab biosimilars found that despite lingering concerns about their usage for extrapolated indications, bevacizumab biosimilars are regularly used in metastatic colorectal cancer (mCRC) even though clinical tests only evaluate them in patients with lung cancer.

Biosimilars Check In: Vegzelma Launch, BLA Acceptances, China Approval

April 26th 2023

By Skylar Jeremias

Article

Over the past week, Vegzelma, a bevacizumab biosimilar, launched in the United States; 2 biologics license applications (BLAs) for biosimilars were accepted for review by the FDA; and China’s regulatory agency approved a denosumab biosimilar.

Dr Andre Harvin Explains His Excitement for Neulasta Onpro Biosimilars

April 23rd 2023

By Skylar Jeremias

Video

Andre Harvin, PharmD, executive director of pharmacy and oncology services at Cone Health, expressed staunch belief that biosimilars referencing Neulasta Onpro, the on-body injector version of reference pegfilgrastim, are one of the most exciting things coming to the supportive cancer care space.

Study Reveals Factors That Dissuade Commercial Plans From Covering Biosimilars

April 19th 2023

By Skylar Jeremias

Article

A study assessing factors that may determine a commercial health plan’s likelihood of covering a biosimilar found that biosimilars that are cancer therapies, used to treat children, indicated for highly prevalent conditions, or only competing against the originator were more likely to have coverage restrictions.